Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506
|
|
- Sherilyn Owens
- 6 years ago
- Views:
Transcription
1 Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA Professional Address: Chest Diseases of Northwestern PA 3580 Peach Street--Suite 103 Erie, Pennsylvania Phone: (814) PERSONAL: Date of Birth: April 5, 1964 Citizenship: USA Married: Christina Children: Alexa (1994), Ashlynn (1996), Lindsey (1999); Evan (2002) EMPLOYMENT: EDUCATION: Chest Diseases of NW PA 3580 Peach Street Suite 103A Erie, PA August 1, 1997 to Present Gannon University Erie, Pennsylvania B.S. in Science, 1986 Honors Dean s List (1986) University of Osteopathic Medicine and Health Sciences Des Moines, Iowa Doctor of Osteopathy, 1990 University of Osteopathic Medicine and Health Sciences, Undergraduate: Gannon University , B.S. INTERNSHIP: Cleveland Clinic Foundation Cleveland, Ohio Internal Medicine RESIDENCY: Cleveland Clinic Foundation Cleveland, Ohio Internal Medicine
2 FELLOWSHIP: Thomas Jefferson University Hospital Division of Pulmonary & Critical Care Pulmonary & Critical Care Medicine July July 1997 The Lakenau Hospital Department of Pulmonary Medicine Sleep Disorder Center July July 1997 CERTIFICATION & LICENSURE: 1994 Diplomat, American Board of Internal Medicine 1996 Diplomat, American Board of Internal Medicine, Pulmonary 1996 Pennsylvania License # OS L 1997 American Board of Internal Medicine, Critical Care Medicine 2011 American Board of Internal Medicine, Sleep Medicine SOCIETY MEMBERSHIPS: American College of Physicians American Medical Association American Thoracic Society American College of Chest Physicians Pennsylvania Thoracic Society Division Chief, Pulmonary Medicine, Hamot Medical Center AWARDS: Golden Apple, Distinguished Teachers Award at Saint Vincent Family Medicine 1998 Roland E. Miller Distinguished Teachers Award Hamot Medical Center Family Medicine 2001 Teacher of the Year Award, Hamot Medical Center 2002, 2004, 2008, 2010 Outstanding Clinical Educator, Saint Vincent Health Center 1998 PROFESSIONAL EXPERIENCE: Clinical Associate Staff Department of General Internal Medicine Cleveland Clinic Foundation
3 Associate Staff of Emergency Medicine Department of Emergency Medicine Cleveland Clinic Foundation Division Head of Pulmonary Medicine Hamot Medical Center present Clinical Pulmonary/Critical Care Medicine Saint Vincent Health Center present Hamot Medical Center present TB Clinician Erie County Health Department present Pulmonary/Critical Care Medicine Veterans Administration Medical Center present Co-Director of Saint Vincent Health Center Sleep Lab present PRESENTATIONS: Eosinophilic Granuloma And Other Interstitial Lung Diseases Presented to the Philadelphia Laennec Society of Medicine. March 12, 1996 Multidisciplinary Approach To The Care of The Pulmonary Critical Care Patient: Meeting Pulmonary Challenges Today and Tomorrow, Symposium for the Critical Care Nursing Continuing Education. Thomas Jefferson University. April 24, Asthma Diagnosis and Management. Presented to the Division of Medicine, Lankenau Hospital. December 11, Sleep Deprivation: From Internship to Sleep Apnea. Presented to the Practical Pulmonology Seminar. September 23, 1998.
4 Controversy of Antibiotic Use in Acute Exacerbation of COPD. Presented to the Practical Pulmonology Seminar. September 22, Where Does Volume Reduction Stand in the Role of the Patient with COPD? Presented to the Practical Pulmonology Seminar. September 20, 2000 RESEARCH EXPERIENCE: Pulmonary Research Fellow Thomas Jefferson University Hospital James E. Fish, MD; Director Stephen P. Peters, MD, Ph.D.: Associate Director Adept in: --Methacholine Challenge Testing --Antigen Whole Lung Challenge Testing --Bronchoscopic Segmental Antigen Challenge --Bronchoalveolar Lavage & Peripheral Blood Cell Separation by Density Gradient and Immunomagnetics --Gel Electrophoresis --Western Blot Analysis --Immunohistochemistry --ELLISA PUBLICATIONS: CHAPTERS: Rowane, J: Hemoptysis, in Rankel (ed); Saunders Manual of Medical Practice, 1st Edition, 1996 ABSTRACTS: Production of IL-8 By Peripheral Blood And BAL Eosinophils From Allergic Asthmatics. J. Rowane, J. Zangrilli, J.R. Shaver, S.K. Cho, F. Leone, J.E. Fish, S.P. Peters. Am J Resp Crit Care Med 153(4); A216, April The Use of a Formal Ethics Curriculum During Critical Care Fellowship Training: A National Survey. G.C. Kane, F.T. Leone, J.E. Rowane, J.E. Fish. Am J Resp Crit Care Med 153(4); A82, April 1996.
5 IL-10 Production by Alveolar Macrophages (M/M) in Asthmatic and Controls Following Segmental Antigen Challenge. J. Rowane, M. Pollice, F.T. Leone, J.E. Fish, S.P. Peters, Am J Resp Crit Care Med 155(4): A757, April 1997 STUDY TRIALS Pulmonary: 1. A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Multicenter Trial to Determine the Efficacy of Oral Zafirlukast (ACCOLATE) When Administered According to Current Labeling Instructions or Subjects With Asthma Receiving Inhaled B2-Agonist in Combination With Inhaled Corticosteroids (ICS). Sub-Investigator 2. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral SB mg. Once Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis. Sub-Investigator 3. A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (Raxar) in the Treatment of Patients with Community Acquired Pneumonia. Sub-Investigator 4. A 12-Week, Randomized, Double-Blind, Positive Control, Crossover Study of Albuterol, Ipratropium, and the Combination, as an Inhalation Solution in Patients with Chronic Obstructive Pulmonary Disease. Sub-Investigator 5. A Randomized, Double-Blind, Double-Dummy, Multicenter Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR, Two Tablets Equal to 2000/125 mg. Twice Daily for 7 Days Versus Oral Clarithromycin 500 mg. Twice Daily for 7 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis. Sub-Investigator 6. An Open, Non Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg. Twice Daily for 7 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults. Sub- Investigator 7. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Intravenous Gemifloxacin Followed by Oral
6 Gemifloxacin versus Intravenous Ceftriaxone Followed by Oral Levofloxacin in the Treatment of Nosocomial Pneumonia (NP) in Adults in Low Risk for Infection with Pseudomonas Aeruginosa. Sub-Investigator 8. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin (Factive) 320 mg. Once Daily for 5 Days Versus Oral Levofloxacin 500 mg. Once Daily for 7 Days for the Treatment of Acute Exacerbations of Chronic Bronchitis. Sub-Investigator. 9. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Investigate the Long-Term Effects of Salmeterol/Fluticasone Propionate 50/500ug bd, Salmeterol 50ug bd and Fluticasone Propionate 500ug bd, All Delivered via the Diskus/Accuhaler Inhaler, on the Survival of Subjects with Chronic Obstructive Pulmonary Disease Over 3 Years of Treatment. Sub-Investigator 10. A Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 5 Days Versus 7 Days in the Treatment of Adults with Acute Exacerbations of Chronic Bronchitis. Sub-Investigator 11. A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort Turbuhaler and The New Version of Pulmicort Turbuhaler in Asthmatic Adults and Adolescents Currently Treated with Inhaled Steroids. Sub-Investigator 12. A Randomized, 12-week, Double-blind, Placebocontrolled, parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding Cilomilast (ARIFLO) 15 mg. Twice Daily to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). 13. A 52-week, randomized, double-blind, single-dummy, parallel group, multicenter Phase III study comparing the long-term safety of SYMBICORT pmdi 160/4.5 ug x 4 actuations twice daily to SYMBICORT pmdi 160/4.5 ug x 2 actuations twice daily and budesonide HFA pmdi 160 ug x 4 actuations twice daily in adult and adolescent subjects with asthma. (Protocol: 0728)
7 14. A Placebo-Controlled Comparison of Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated with Inhaled Steroids. (Protocol: 0620). 15. A Twelve-Week, Randomized, Double-Blind, Double- Dummy, Placebo and Active Controlled Study of SYMBICORT pmdi Administered Once Daily in Adults and Adolescents with asthma. (Protocol: 0726). 16. A Long Term Safety Study of Levalbuterol and Racemic Albuterol in Sujbects Twelve Years of Age and Older with Asthma. (Protocol: ). 17. A Randomized, 24-week, Double-blind, Placebocontrolled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (Protocol: CIL103657) 18. A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50 mcg BID with Salmeterol Diskus 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with COPD. (Protocol: SCO100250) 19. A 6-Month Double-Blind, Double-dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort pmdi 2 x 160/4.5 mg bid and 2 x 80/4.5 mg bid Compared to Formoterol TBH, Budesonide pmdi (& the combination) & Placebo in COPD patients. (protocol: D5899C00002) 20. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Elderly Patients with Primary Insomnia. (protocol: MK-0928) 21. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Adult Patients with Primary Insomnia. (protocol: MK-0928) 22. A 26-week treatment, multi center, randomized, doubleblind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 ug o.d.) in patients with chronic
8 obstructive pulmonary disease using blinded formoterol (12 ug b.i.d.) and open label triotropium (18 ug o.d.) as active controls. (Protocol No.: CQAB149B2335S) 23. A 12-week treatment, multi center, randomized, doubleblind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 ug o.d.) in patients with chronic obstructive pulmonary disease. (Protocol No.: CQAB149B2346) 24. A Phase IIb clinical trial to evaluate the safety, tolerability and immunogenicity of Zoster vaccine in patients on chronic/maintenance corticosteroids. (Protocol No.: V ) 25. A randomized, double-blind, parallel group 12-week comparison of the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a metered-dose-inhaler 230/42 mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50 mcg twice-daily in subjects with COPD. (Protocol No.: ADC ) 26. A double-blind, randomized, placebo-controlled, multi center, parallel group, dose-ranging study of MK-0633 in adult patients with Chronic Asthma. (Protocol No.: ) 27. A 52-week, randomized, double-blind, parallel-group study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (Protocol: ADA109057) 28. A multicenter, randomized, double-blind, placebocontrolled, parallel group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the Combination of GSK and GW administered once-daily in Subjects With COPD (Protocol: DB ) 29. A randomized, double-blind, parallel-group, 24-week study to evaluate the efficacy and safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg Inhalation Powder) BID plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD versus Spiriva QD plus Placebo DISKUS BID
9 in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (Protocol: ADC111114) 30. A randomized, double-blind, controlled, parallel group, 12 week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18µg once daily versus open label tiotropium 18µg once daily in patients with moderate-tosevere chronic obstructive pulmonary disease (Protocol No.: CQAB149B2351) 31. Efficacy and safety of aclidinium bromide at two dose levels (200 µg twice daily, 400µg twice daily) vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD) (Protocol: LAS-MD-33) 32. A Long-term, Randomized, Double-Blind, Extension Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (Protocol: LAS-MD-36) 33. A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of 2 doses of aclidinium bromide compared with placebo for 12 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease followed by a 40-week evaluation of the 2 aclidinium bromide doses (Protocol LAS-MD-38) 34. Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease (ASQ112989) 35. Novartis Pharmaceuticals trial entitled: A randomized, double-blind, double-dummy, placebo-controlled, parallelgroup study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.cqab149b Novartis Pharmaceuticals trial entitled: A 26-week treatment multicenter, randomized, double-blind, parallelgroup, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 mcg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). QVA149A2303
10 37. A 52-week treatment, multi-center, randomized, doubleblind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). CQVA149A A randomized, active-controlled, double-blind, doubledummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK mcg once-daily alone and in combination with GW mcg oncedaily via novel Dry Powder Inhaler (ndpi) in Subjects with Chronic Obstructive Pulmonary Disease (COPD). DB A 24-Week, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease: DB A Phase III, Randomized, Double-blind, Placebo- Controlled Study Evaluating The Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-31.
11 42. A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC- MD A 52-week, double-blind, randomized, placebo controlled parallel group study to evaluate the effect of roflumilast 500 μg on exacerbations in severe to very severe COPD patients treated with fixed dose combination LABA/ICS (Advair 250/50 μg or, Symbicort 160/4.5 μg): ROF-MD A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease: HZC SUMMIT. 45. Novartis Pharmaceuticals trial entitled: A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.) to investigate the effect on FEV 1 in and ACQ patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy: CQAW039A A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC- MD A randomized, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5µg (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) in patients with Chronic Obstructive Pulmonary Disease (COPD): Revised 1/13
12
CURRICULUM VITAE KENNETH D. CHINSKY, M.D.
KENNETH D. CHINSKY, M.D. Chest Diseases of Northwestern PA 3580 Peach Street, Suite 103A Erie, PA 16508 www.chestdiseases.yourmd.com Phone: (814) 864-4755 FAX: (814) 864-5430 Email: Sigsbee@aol.com Home
More informationJeffrey P. McGovern, MD, FCCP, ABSM
Jeffrey P. McGovern, MD, FCCP, ABSM 3580 Peach Street--Suite 103A Erie, PA 16508 814-864-4755 (Home: 814-868-1155) Date of Birth: March 10, 1960 Spouse: Kathleen Medical Licenses:, Pennsylvania MD047962L
More informationJORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA Office:
JORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA 16508 Office: 814-864-4755 WORK EXPERIENCE March 2011 - present Chest Diseases of Northwestern
More informationRonald H. Saff, M.D. Curriculum Vitae
Ronald H. Saff, M.D. Curriculum Vitae Address 2300 Centerville Road Tallahassee, FL 32308 (850) 766-7886 ronsaff@aol.com Certification Board Certified Internal Medicine, September 1992 Board Certified
More informationCURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP
CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP Business address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, Fl Phone: 941.951.3920 Fax: 941.951.3922 Prior business
More informationCURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP
CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP Present Business Address: Prior Business Address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, FL 34239 Telephone: 941-951-3920
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationCURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP
CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP Present Business Address: Prior Business Address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, FL 34239 Telephone: 941-951-3920
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationCurriculum Vitae, Edward H. Ortiz, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: FutureSearch Trials
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAsthma and COPD Drug Discoveries:
Asthma and COPD Drug Discoveries: What the future holds World Leaders in Health Industry Analysis Asthma and COPD Drug Discoveries: what the future holds ISBN: 1 85822 264 8 Copyright 2006 Espicom Business
More informationCurriculum Vitae, Ward Jackson Paine, M.D. Ward Jackson Paine, M.D. Exemplar Research, Inc Mileground Road Morgantown, WV 26505
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Ward Jackson Paine,
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology. Medical Doctor (M.D.
CURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology PRIMARY OFFICE ADDRESS: St. Francis Sleep Allergy & Lung Institute 802 N. Belcher Road Clearwater,
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationPrincipal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report.
(For national authority SYNOPSIS use only) Date 3 March 2005 An open, randomized, two-way crossover study evaluating the pharmacokinetics of budesonide and formoterol from Symbicort pmdi versus Oxis Turbuhaler
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationSUBURBAN LUNG ASSOCIATES, S.C. 800 Biesterfield Road, Suite 510 Elk Grove Village, IL 60007
SUBURBAN LUNG ASSOCIATES, S.C. 800 Biesterfield Road, Suite 510 Elk Grove Village, IL 60007 NAME...EDWARD J. DIAMOND MD, FCCP, MBA PROFESSIONAL EMPLOYMENT..President Suburban Lung Associates, S.C. Elk
More informationFDCs for CO PD: From Famine to a Feast of Therapeutic Choices
FDCs for CO PD: From Famine to a Feast of Therapeutic Choices LAURA RUNKEL, PhD Associate Director, CNS, AutoImmune/Inflammation, Ophthalmology Historically, there have been few therapies developed for
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationInhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationTreatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes
Patient Related Outcome Measures open access to scientific and medical research Open Access Full Text Article Review Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationQuestion I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationUsing Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationExercise and Asthma: What patients and doctors can do to improve outcomes
Exercise and Asthma: What patients and doctors can do to improve outcomes Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Program Director Penn State University Hershey, PA,
More information